MYC and familial pancreatic carcinoma: Clinical data indicate that 43.5% of pancreatic cancer patients frequently present with c-Myc overexpression and aberrant activation, which means that c-Myc is closely related to the development of pancreatic cancer (Schleger et al., 2002).